06/24/22 6:30 AMNYSE : EBS Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine CandidateEmergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted). AV7909 is the company’s newRHEA-AIneutral
06/21/22 6:30 AMNYSE : EBS clinical trialEmergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious DiseasesEmergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP)RHEA-AIneutral
06/02/22 8:20 AMNYSE : EBS conferencesEmergent BioSolutions to Participate in Investor ConferencesEmergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: Benchmark Healthcare House Call Virtual 1X1 Conference June 2, 2022 NYSERHEA-AIneutral
05/16/22 6:32 AMNYSE : EBS acquisitionEmergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All AgesExpands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threat Transaction to be funded with currently available funds; Expected to be accretive beginning with anticipated productRHEA-AIneutral
05/12/22 6:30 AMNYSE : EBS Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDTEmergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ANNUALRHEA-AIneutral
04/28/22 4:05 PMNYSE : EBS earningsEmergent BioSolutions Reports Financial Results For First Quarter 2022Emergent BioSolutions Inc. (NYSE: EBS) today reportedRHEA-AIneutral
04/08/22 6:30 AMNYSE : EBS earningsEmergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2022, recent business developments, revenue guidance for theRHEA-AIneutral
03/23/22 4:05 PMNYSE : EBS Emergent BioSolutions Provides Corporate Governance UpdateEmergent BioSolutions Inc.RHEA-AIvery positive
03/14/22 4:05 PMNYSE : EBS conferencesEmergent BioSolutions to Participate in Investor ConferencesEmergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: KeyBanc Life Sciences & MedTech Investor Forum March 22, 2022 CompanyRHEA-AIneutral
03/11/22 6:34 AMNYSE : EBS clinical trialEmergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide PoisoningEmergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN), a treatmentRHEA-AIneutral